The Filing Desk

Arcturus Therapeutics vs Assembly Biosciences

Arcturus Therapeutics ARCT · Assembly Biosciences ASMB · Pharmaceuticals

Arcturus Therapeutics reported revenue of $82 million in fiscal 2025, about the same as Assembly Biosciences' $72 million in fiscal 2025. Arcturus Therapeutics' revenue fell 46.1% in its latest year, and Assembly Biosciences' grew 153.5%. Arcturus Therapeutics had an operating margin of -93.0%, against -16.8% at Assembly Biosciences. Free cash flow was −$74 million at Arcturus Therapeutics and −$41 million at Assembly Biosciences.

Side by side

Arcturus TherapeuticsAssembly Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$82M$72M
Revenue growth−46.1%153.5%
Revenue growth a year, last 5 years53.9%−1.8%
Gross margin——
Operating margin−93.0%−16.8%
Net margin−80.2%−8.5%
Free cash flow−$74M−$41M
Free cash flow margin−90.8%−56.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.4%86.7%
Last close$7.60$22.50
P/E at the last close——
Insider trades, last 12 months—sold $14,687
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcturus TherapeuticsAssembly Biosciences
Operating margin
Percent of revenue
Arcturus TherapeuticsAssembly Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcturus TherapeuticsAssembly Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcturus Therapeutics and Assembly Biosciences pages.